Scholar Rock Holding closed at $46.09 on Nov 4, up 4.80%, 23.2% below its 52-week closing high. Volume of 1.7M shares was 1.03× its 20-day average (close to normal).
Split-adjusted performance: +8.6% over one month, -2.2% over six months, +60.1% over one year.
Short interest was 22.2M shares at the Oct 15 settlement, down 2.4% from the prior report (20.3% of float, 12.7 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SRRKScholar Rock Holding | $46.09 | +4.80% | −2.2% | — | — | — | $5.61B | |
| CGONCG Oncology | $67.71 | +5.70% | −0.4% | — | −6832.8% | — | $6.00B | Compare |
| IMVTImmunovant | $29.90 | +2.96% | +4.3% | — | — | — | $6.18B | Compare |
| KODKodiak Sciences | $98.51 | −0.38% | +114.7% | — | — | — | $6.19B | Compare |
| CRSPCRISPR Therapeutics AG | $51.78 | +3.57% | −6.0% | +1325.1% | −879.6% | — | $5.01B | Compare |
| ADPTAdaptive Biotechnologies | $26.71 | +3.53% | +85.1% | +21.5% | −55.6% | — | $4.26B | Compare |
| RLAYRelay Therapeutics | $18.03 | +3.38% | +39.6% | −48.3% | −23916.3% | — | $3.95B | Compare |
| IOVAIovance Biotherapeutics | $8.70 | −1.47% | +112.7% | +65.7% | −47.6% | — | $3.94B | Compare |
| KRYSKrystal Biotech | $310.84 | +1.90% | +7.6% | +30.2% | 49.5% | 40.9 | $9.20B | Compare |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
